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introduction: Fluorine-18-fluorodeoxyglucose positron-emission tomography (18F-FDG-
PET) is widely used to help localize the hypometabolic epileptogenic focus for presurgical 
evaluation of drug-refractory epilepsy patients. Two voxel-based brain mapping methods 
to interpret 18F-FDG-PET, statistical parametric mapping (SPM) and three-dimensional 
stereotactic surface projection (3D-SSP), improve the detection rate of seizure foci. This 
study aimed to compare the consistency of epileptic focus detection between SPM and 
3D-SSP for 18F-FDG-PET brain mapping analysis.
Methods: We retrospectively reviewed the clinical, electroecephalographic, and brain 
imaging results of 35 patients with refractory epilepsy. 18F-FDG-PET studies were reval-
uated by SPM, 3D-SSP, and visual assessment, and the results were compared to the 
magnetic resonance imaging (MRI) lesion location and to the presumed epileptogenic 
zone (PEZ) defined by video-electroencephalogram and other clinical data. A second 
consistency study compared PET analyses to histopathology and surgical outcomes in 
the 19 patients who underwent lesion resection surgery.
results: Of the 35 patients, consistency with the PEZ was 29/35 for SPM, 25/35 for 
3D-SSP, 14/35 for visual assessment, and 10/35 for MRI. Concordance rates with the 
PEZ were significantly higher for SPM and 3D-SSP than for MRI (P < 0.05) and visual 
assessment (P <  0.05). Differences between SPM and 3D-SSP and between visual 
assessment and MRI were not significant. In the 19 surgical patients, concordance with 
histopathology/clinical outcome was 14/19 for SPM, 15/19 for 3D-SSP, 14/19 for visual 
assessment, and 9/19 for MRI (P > 0.05). A favorable Engel outcome (class I/II) was 
found in 16 of 19 cases (84%), and failure of seizure control was found in 3 of 19 patients 
(class III/IV).
conclusion: Voxel-based 18F-FDG-PET brain mapping analysis using SPM or 3D-SSP 
can improve the detection rate of the epileptic focus compared to visual assessment 
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inTrODUcTiOn
Up to 30% of individuals with epilepsy are estimated to be 
drug resistant, which was defined when epilepsy remains 
uncontrolled despite two adequate trials of antiepileptic drugs 
that were appropriate for the person’s disease (1), and these 
cases are challenging to manage (1–3). Fortunately, resective 
surgery can reduce or eliminate seizure occurrence for most 
cases and can be a powerful means of treating people with 
drug-resistant epilepsy (DRE). Seizures originate from one 
or more epileptogenic zones, and successful seizure control 
depends on their complete removal. Therefore, identification 
and precise localization of the epileptic focus is imperative for 
achieving optimal results following epilepsy surgery. Routine 
presurgical evaluation methods include semiology, computed 
tomography (CT), magnetic resonance imaging (MRI), elec-
troencephalogram (EEG), and positron-emission tomography 
(PET) (4). Although intracranial EEG evaluation remains the 
gold standard for focus localization, surgical invasiveness and 
concomitant risks limit widespread use (5). Structural imaging 
by MRI can detect anatomic abnormalities (lesions) associ-
ated with epileptic focus, but many foci are MRI-negative. 
Alternatively, radionuclide imaging techniques, such as 
fluorine-18-fluorodeoxyglucose positron-emission tomography 
(18F-FDG-PET), identify functional brain abnormalities. Uptake 
of 18F-FDG measures regional cerebral glucose metabolism, 
which is often reduced in epileptic foci (6).
In clinical practice, a brain region with hypometabolism 
of 18F-FDG-PET is generally deemed to closely overlap with 
the epileptic foci during the interictal state (7). However, the 
accuracy of 18F-FDG-PET detection is still debated. For instance, 
Dellabadia et al. (8) reported a sensitivity of 86%, but Khan et al. 
(6) found only 59% sensitively, and Kumar et  al. (9) reported 
35–71% accuracy for identifying the resection site. These differ-
ences likely result from the methods used to analyze FDG-PET 
scans. Mainstream approaches to interpret PET results include 
subjective visual interpretation and objective methods, such as 
voxel-based statistical analysis with statistical parametric map-
ping (SPM) (10–14). Three-dimensional stereotactic surface 
projection (3D-SSP) with a different voxel-based computing 
paradigm, developed by Minoshima et al. (15), has been used to 
evaluate the spatial distribution of abnormal regional cerebral 
blood flow (rCBF) in SPECT and has also been applied to PET 
analysis, especially for Alzheimer’s disease lesions (characterizing 
AD with a 18F-FDG PET-specific pattern of prominent parieto-
temporal and posterior cingulate cortex hypometabolism using 
3D-SSP.) (16), with encouraging results (17–19). A few previous 
epilepsy studies attempted to localize the epileptic focus using 
3D-SSP. For instance, Singhal et  al. (20) reported that 3D-SSP 
identified the hypometabolic zone corresponding to the surgi-
cal site in 36 of 40 cases (90%). However, no study has directly 
compared the accuracy of 3D-SSP to SPM for epileptic focus 
localization.
The purpose of our study was to compare 3D-SSP to SPM 
using the presumed epileptogenic zone (PEZ, defined by scalp 
video-EEG or invasive subdural EEG) as standards, which was 
verified by postoperative histology and outcomes in a proportion 
of patients.
MaTerials anD MeThODs
Patients
From June 2014 to June 2015, we retrospectively reviewed 76 
cases of medically intractable epilepsy evaluated for possible 
vagus nerve stimulation (VNS) therapy at our epilepsy center. 
The presurgical evaluation includes one or more of the follow-
ing: seizure semiology, neurologic examination, brain MRI, 
interictal 18F-FDG-PET, and 24-h video scalp EEG monitor-
ing. If the results were ambiguous or inconclusive, subdural 
EEG examination using strip and grid or depth electrodes was 
performed on the suspected area before surgery. Ultimately, the 
PEZ was defined by the scalp or subdural EEG results and clini-
cal data (seizure semiology, neurologic examination). Patients 
were included in the study who met the following criteria: 
(a) patients had been diagnosed with intractable epilepsy by 
epileptologists according to the International League Against 
Epilepsy (ILAE) definition of DRE in 2009 (1); (b) patients 
should undergo sufficient preoperative assessment, including 
electrical physiological examination (scalp or subdural EEG), 
brain MRI, and interictal 18F-FDG-PET; then, 19 cases were 
excluded for whom the origin of epilepsy in MRI was completely 
concordant with video-EEG, and 18F-FDG-PET imaging was not 
conducted; and (c) the anatomical structure should be complete 
in the T1-weighted MRI, and not destructed by the suspect 
epileptic sites and surgical operation. Thirteen patients had 
significant space occupying lesions on MRI, such as glioma or 
dysembryoplastic neuroepithelial tumor (DNET), resulting in 
severe distortion of the surrounding tissues, and nine patients 
had undergone failed epilepsy surgery resulting in a clear brain 
tissue defect. Brain tissue defects and deformation are likely to 
cause errors in PET analysis (failure in PET data normalization), 
so these 22 patients were excluded. Finally, 35 patients (26 males, 
9 females) aged 10–47 years (mean ± SD, 24 ± 11 years) were 
included in the study, as listed in Table 1.
and MRI. Consistency with PEZ was similar between SPM and 3D-SSP; according to 
their own characteristics, 3D-SSP is recommended for primary evaluation due to greater 
efficiency and operability of the software, while SPM is recommended for high-accuracy 
localization of complex lesions. Therefore, joint application of both software packages 
may be the best solution for FDG-PET analysis of epileptic focus localization.
Keywords: epilepsy, statistical parametric mapping, 18F-FDg-PeT, 3D-ssP, epileptic focus
TaBle 1 | The complete information of the all 35 patients, including imaging results, pathology results, and surgical outcome.
no. sex age(y) Mri sPM-PeT 3D-ssP Visual-PeT PeZ surgery Pathology engel
1 F 28 N L T L T L T L T L ant_T resection HS/m_T ulegyria I
2 M 24 N L T L T L T L T L ant_T resection HS/m_T FCD I
3 M 24 L T–P–O L T–P–O (FDR) L T–P–O L T–P–O L T–P–O L T–P–O lesion resection FCD II
4 M 6 R T R T R T R T R T R ant_T resection HS/m_T sclerosis I
5 M 44 N R O R T R T R T R ant_T resection HS/m_T sclerosis I
6 M 24 N R T–P–O R T–P–O R P R T–P–O R T–P–O lesion resection FCD I
7 M 31 L T L F L F L T L T L ant_T resection HS/m_T sclerosis I
8 M 10 R T R T/T–O/F (FDR) R T/T–O R T/P/O R T R post_T resection encephalitis IV
9 M 20 N R T R T R T R T R ant_T resection HS/m_T sclerosis I
10 F 37 L T L T L T L T L T L ant_T resection HS/m_T FCD I
11 M 38 N R T R T N R T R ant_T resection HS/m_T sclerosis I
12 M 10 R insular R P/insular R T–P–O R P/T R insular R insular lesion resection FCD III
13 M 18 R F R F/T R T R F/T R T/F R ant_T resection;  
R F lesion resection
FCD II
14 F 28 L T L T L T L T L T L ant_T resection HS/m_T sclerosis I
15 M 38 L T L T L T L/R T L T L ant_T resection HS/m_T sclerosis I
16 M 25 N R T R T R T R T R ant_T resection HS/m_T FCD I
17 M 16 N L T L T L T L T L ant_T resection HS/m_T sclerosis III
18 M 16 N N N R T R T R ant_T resection HS/m_T FCD I
19 M 34 L T L T L T N L T L ant_T resection HS/m_T sclerosis I
20 F 10 N R F/P/SMA (FDR) DIFF L/R cerebellum R SMA VNS
21 F 10 R T L/R T (FDR) L/R T N R/L T VNS
22 M 18 L T R T–P–O L F R F R T VNS
23 M 10 N L/R cerebellum L/R cerebellum N L/R cerebellum VNS
24 M 12 L/R F L/R cerebellum L/R cerebellum N L/R cerebellum VNS
25 M 18 N DIFF L/R cerebellum N L/R cerebellum VNS
26 M 29 N DIFF DIFF N DIFF VNS
27 F 11 N L/R T L/R T N L/R T VNS
28 M 21 N L/R cerebellum L/R cerebellum R F L/R cerebellum VNS
29 M 25 R T–P–O R T–P–O NONE N R primary motor VNS
31 F 28 N DIFF DIFF N DIFF AED
32 F 24 N L T–P–O N N L primary motor AED
32 M 22 N L F/P DIFF N L primary motor AED
33 M 47 N DIFF DIFF N DIFF AED
34 F 47 N DIFF DIFF N DIFF AED
35 M 42 N R SMA/F DIFF N R SMA AED
y, year; F, female; M, male; L, left; R, right; T, temporal lobe; P, parietal lobe; F, frontal lobe; O, occipital lobe; SMA, supplementary motor area; ant_T, anterior temporal lobe; post_T, 
posterior temporal lobe; m_T, medial temporal lobe; T–P–O, junction of temporal–parietal–occipital lobe; T–O, junction of temporal–occipital lobe; T/P/O, all temporal lobe, parietal 
lobe, and occipital lobe. DIFF, diffuse into multi-lobes; N, normal; VNS, vagus nerve stimulation; AED, antiepileptic drugs; HS, hippocampal sclerosis; FCD, focal cortical dysplasia. 
FDR, FDR corrected.
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For SPM analysis, 25 healthy volunteers (20 men and 5 women, 
mean ± SD, 27 ± 5 years) who underwent physical examinations 
including whole-body PET at our PET Imaging Center served 
as controls. All PET scanning results in the control group were 
confirmed as normal. All controls were right-handed with no 
history of neurological, psychological, or severe medical illness 
requiring drugs known to affect brain 18F-FDG-PET studies. 
Informed written consent was obtained from all patients, and all 
procedures were approved by the Beijing Tiantan Hospital Ethics 
Committee.
Video-EEG monitoring and MRI imaging is detailed in the 
Supplementary Material and Table 1.
18F-FDg PeT imaging
All patients fasted for 4  h before 18F-FDG injection. Thirty-
seven MBq of 18F-FDG per ten kilogram of body weight was 
injected intravenously in the awake and resting state, and PET 
image acquisition was started about 60  min after injection. 
The 18F-FDG-PET studies were performed using a GE Discovery 
690 Medical system (Discovery ST, GE Healthcare, Waukesha, 
WI, USA). Computed attenuation correction was utilized to cor-
rect for attenuation of 511-keV photons. Emission images were 
reconstructed in a 192 ×  192 ×  47 matrix with a voxel size of 
1.56 × 1.56 × 3.27 in the axial direction using the ordered subsets 
expectation maximization algorithm, with 5 iterations and 32 
subsets, and corrected for attenuation using the CT transmission 
scan. To increase comfort and reduce fear and anxiety during the 
18F-FDG uptake period, patients were not monitored by scalp 
EEG. However, no visible seizure events occurred. Sedation was 
adopted when necessary. Heart rate, blood pressure, and pulse 
oximetry were measured during PET.
18F-FDg PeT analysis
Visual Evaluation
Fluorine-18-fluorodeoxyglucose positron-emission tomography 
images were visually evaluated (visual-PET) by two investigators 
with expertise in reading PET images of the epileptic brain. The 
PET visual evaluators and data analysts of SPM and 3D-SSP were 
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unaware of the findings of the video-EEG and MRI, and were 
blinded to the location of the PEZ. Hypometabolic brain areas 
were identified by consensus based on differences with regional 
uptake in the contralateral hemisphere.
SPM Analysis
Fluorine-18-fluorodeoxyglucose positron-emission tomography 
data were analyzed voxel-by-voxel using SPM8 (Wellcome 
Department of Cognitive Neurology, University College, 
London, UK) running on Matlab (Mathworks Inc., Sherborn, 
MA, USA) as described (21–23). First, PET images were co-
registered with the SPM template T1-weighted MR reference 
to enable visualization and localization of activation loci. 
Co-registered PET images were then spatially normalized into 
a common Montreal Neurological Institute (MNI) atlas ana-
tomical space following a 12-parameter affine transformation 
and non-linear transformations, yielding images composed of 
2 mm × 2 mm × 2 mm voxels. Third, normalized images were 
smoothed with FWHM  =  12  mm using Isotropic Gaussian 
Kernel to increase the signal to noise ratio.
Subsequently, preprocessed PET image values were corrected 
to a mean value of 50 mL/dL/min by “proportional scaling” to 
reduce individual variation. A mask with 0.8 intensity value was 
used to select only voxels with activity and to exclude extra cranial 
activities. A two-sample t-test, based on the specified contrasts 
(hypometabolism in patients), was applied between individual 
patient data and the control group and to best reduce the impact 
of age and gender, both factors were regressed out as covariates. 
The resulting P value and extended voxel size (k) were thresholded 
at two levels and three levels, respectively: P < 0.001 (matched 
with k > 50, 100, 200 voxel corrected, respectively) and P < 0.01 
(matched with k >  50, 100, 200 voxel corrected, respectively). 
What’s more, we choose the little P value first, but the central 
hypometabolic regions should have been kept unchanged among 
at least two voxel sizes simultaneously.
3D-SSP Analysis
NEUROSTAT 3D-SSP software (University of Michigan, Ann 
Arbor, MI, USA) conducts quantitative statistical analyses based 
on voxel computation (15). First, PET data were converted from 
the “dicom” format to a 32-bit REAL binary format supported 
by default in 3D-SSP. Second, we reduced the image size to 
128 × 128 from 192 × 192. Individual PET images were analyzed 
automatically using 3D-SSP software. Patient PET data were 
compared to the age-matched healthy control group (embedded 
in the 3D-SSP), with voxel-by-voxel Z-score analysis after voxel 
normalization to values of four reference regions, global mean, 
pontine, cerebellar, and thalamus, where Z score  =  [(control 
mean) − (individual value)]/(control SD) as previously reported 
by Minoshima et  al. (15). Deviations from normal values are 
expressed as a 3D-SSP Z-score map from the projection of lateral, 
anterior, posterior, superior, inferior, and medial views.
surgical Treatment and Follow-up
A subset of patients (19/35) with a definite epileptic zone (EZ) 
and no operative contraindications underwent resection surgery, 
including lobar or multi-lobar selective cortical resection. All 
resected brain tissues were sent to the neuropathology depart-
ment for histopathologic analysis.
Postsurgical outcome was evaluated 6−14  months later 
(mean ± SD, 10 ± 3 months) according to Engel’s classification 
(24): class I (completely seizure-free, auras only, or atypical early 
postoperative seizures only), class II (≥90% seizure reduction or 
nocturnal seizures only), class III (≥50% seizure reduction), and 
class IV (<50% seizure reduction). Patients were then divided 
into two subgroups: favorable outcome (Engel class I/II) and 
non-favorable outcome (Engel class III/IV).
statistical analysis
All neuroimaging and analysis results were revaluated by brain 
imaging experts and epilepsy specialists, and the location of the 
PEZ was determined. The following measures were introduced 
to classify the results. (i) Consistency study (CS) to see if the 
result was concordant with the PEZ; (ii) positive-consistency 
study (PCS) to see if the result was not concordant with the 
PEZ, but the EZ was in the same hemisphere as the PEZ; (iii) 
negative-consistency study (NCS) to see if the EZ location was in 
the contralateral hemisphere, or bilateral lesions were predicted 
when the PEZ was unilateral; and (iv) normal-study (NS) to see 
if imaging results were normal.
The proportions of each study classification for MRI, SPM-
PET, 3D-SSP-PET, and visual-PET relative to PEZ are reported. 
Proportions were compared by the McNemar test with P < 0.05 
considered significant. A kappa test was performed, and a 
k-statistic value was also calculated to measure the consistency 
rates among modalities. Statistical procedures were performed 
using SPSS (version 20.0; SPSS Inc., Chicago, IL, USA).
resUlTs
Demographic results
There were no significant differences between the demographic 
data of the two groups, including gender (P =  0.76) and age 
(P = 0.15). Chi-square test and Mann–Whitney U-test were per-
formed for gender and age between epileptic patients and healthy 
controls, respectively.
seizure localization by Mri, sPM-PeT, 
3D-ssP-PeT, and Visual-PeT
The epilepsy surgeon was able to define a clear PEZ in 31 of 35 
patients (89%) by combining clinical data and video-EEG. In the 
remaining four patients, video-EEG showed dispersed activity 
and failed to detect single or specific seizures. All localization 
results were shown in Table 2 and Figure 1.
Magnetic resonance imaging findings were abnormal in 14 of 
35 patients (40%). In 10 of 35 cases (29%), the MRI lesion was 
concordant with PEZ (CS), and in 2 of 35 cases (6%), it was not 
concordant but was in the same hemisphere (PCS). The other 
2 cases were classified as NCS. No abnormalities were found in 
21 of 35 (60%) MRI studies (NS).
According to visual evaluation, PET findings were abnormal 
in 20 of 35 patients (57%); 14 of 35 cases (40%) were classified as 
CS, 4 as PCS, and 2 as NCS. PET studies were classified as normal 
by visual evaluation in 15 of 35 cases (43%).
TaBle 2 | classification of patients.
imaging 
modality
normal-
study (ns)
consistency 
study (cs)
Positive-
consistency  
study (Pcs)
negative-
consistency 
study (ncs)
(a) all 35 patients
MRI 21 10 2 2
VIS-PET 15 14 4 2
SPM-PET 1 29 5 0
3D-SSP-PET 3 25 3 4
(B) 19 patients undergoing surgery
MRI 9 9 1 0
VIS-PET 2 14 2 1
SPM-PET 1 14 4 0
3D-SSP-PET 1 15 3 0
FigUre 1 | concordance of localization for each modality relative to 
the presumed epileptogenic zone (PeZ).
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Statistical parametric mapping-PET findings were abnormal 
in 34 of 35 patients (97%), with 29 of 35 (83%) classified as CS 
and 5 as PCS. In one case (case 18), SPM-PET could not localize 
the epileptic focus. A more comprehensive analysis localized the 
epileptic foci to the right temporal lobe, according to the semiol-
ogy and EEG results.
Three-dimensional stereotactic surface projection-PET results 
were abnormal in 32 of 35 patients (91%), with 25 of 35 cases 
(71%) classified as CS, 3 as PCS, and 4 as NCS. 3D-SSP-PET stud-
ies were classified as normal in 3 of 35 cases (9%).
The concordance rate with PEZ was significantly higher using 
computational analyses of PET compared to MRI (SPM-PET: 
83 vs. 29%, P =  0.000, k = −0.115; 3D-SSP-PET: 71 vs. 29%, 
P = 0.001, k = −0.014), while the difference between visual-PET 
and MRI was not significant (40 vs. 29%, P = 0.388, k = 0.25), 
as shown in Figure  2. Combined SPM-PET and 3D-SSP-PET 
results were consistent with PEZ in 32 of 35 cases (91%), while 
combining computational analysis with visual-PET increased 
consistency with PEZ to 34 of 35 cases, significantly higher 
than for MRI (97 vs. 26%, P = 0.000, k = −0.058) (Figure 3). 
Indeed, MRI failed to reveal the epileptogenic lesion accord-
ing to PEZ in 25 of 35 patients (71%). Within this NS group, 
SPM-PET successfully localized the PEZ-defined lesion in 22 
of 25 cases (88%) and 3D-SSP-PET in 18 of 25 cases (72%), 
while visual-PET was consistent with PEZ in only 8 of these 
25 cases (32%).
Computational PET analysis showed higher consistency 
with PEZ than visual-PET (SPM-PET: 83 vs. 40%, P =  0.003, 
k = −0.162; 3D-SSP: 71 vs. 40%, P =  0.013, k =  0.105), and 
visual-PET failed to localize the PEZ-defined epileptogenic lesion 
in 21 of 35 patients (60%). Within this NS group, SPM-PET was 
consistent with PEZ in 19 of 21 cases (90%) and 3D-SSP-PET in 
14 of 21 cases (66%).
Though not significant, SPM-PET was more consistent with 
PEZ than 3D-SSP-PET (83 vs. 71%, P = 0.344, k = 0.205) with fair 
diagnostic consistency, as 3D-SSP-PET analysis failed to reveal an 
epileptogenic lesion that matched PEZ in 10 of 35 patients (29%). 
Within this NS group, SPM-PET was consistent with PEZ in 7 of 
10 cases (70%).
surgical results
A total of 19 patients underwent epileptic foci resection surgery, 
18 single lobectomies, and 1 multi-lobar resection. Pathologic 
analysis of resected tissues revealed nine cases of hippocampal 
and medial temporal lobe sclerosis, four cases of simple focal 
cortical dysplasia (FCD), four cases of hippocampal sclerosis 
combined with medial temporal lobe FCD, one case of hip-
pocampal sclerosis with medial temporal lobe ulegyria, and one 
case of encephalitis.
All surgical patients were followed up for at least 6  months 
(mean ± SD, 10 ± 3 months) after resection surgery. Engel’s class 
I was obtained in 14/19 cases, class II in 2/19, class III in 2/19, 
and class IV (i.e., unchanged) in 1 case. According to the binary 
classification of outcome, 16 of 19 patients (84%) had a favorable 
Engel outcome (class I/II), and 3 of 19 (16%) had an unfavorable 
Engel outcome (class III/IV).
Reasons for the unfavorable clinical outcomes were suggested 
by SPM and 3D-SSP analyses, detailed in Figures  4 and 5. In 
two cases (cases 8 and 12), EZ resection was incomplete as there 
was another epileptic foci aside from the PEZ. Although case 17 
showed good consistency for all diagnostic methods, the resected 
region was likely smaller than the real EZ, so seizure control 
failed. In the favorable outcome group, there was discordance 
between SPM and 3D-SSP results in three cases (cases 5, 7, and 
13) in Figure 6. More specifically, SPM showed PCS in case 5, 
3D-SSP in case 13, and both in case 7.
DiscUssiOn
Voxel-based analysis allows for objective identification of 
regional changes in brain structure and function, thereby 
improving diagnostic accuracy. SPM and 3D-SSP are both 
widely used for voxel-based analysis of brain PET (18, 21, 
25–27). To the best of our knowledge, no study has directly 
compared 3D-SSP to SPM for the evaluation of 18F-FDG-PET 
in intractable epilepsy patients. We demonstrate that 3D-SSP is 
superior for localization compared to MRI and visual analysis of 
18F-FDG-PET for localization, although not as accurate as SPM. 
Nonetheless, combined 3D-SSP, SPM, plus visual 18F-FDG-PET 
analysis was almost perfectly concordant with PEZ. Further, 
3D-SSP and SPM revealed additional epileptogenic foci not 
FigUre 3 | comparison of computational methods (3D-ssP + sPM) to visual-PeT interpretation and all PeT methods to Mri (**P < 0.05).
FigUre 2 | comparison of location concordance relative to PeZ among analysis methods (**P < 0.05, ##P > 0.05).
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found by PEZ that may be related to the poor outcome in 
several patients.
While not commonly applied for localization of epileptic foci, 
3D-SSP has been shown to accurately distinguish the early stage 
of Alzheimer’s disease (mild cognitive impairment), frontotem-
poral dementia, and dementia with Lewy bodies from matched 
controls (16, 28, 29). In contrast to the SPM “two-sample t-test” 
calculation model, 3D-SSP uses a distinct Z-score calculation. 
Buchholz et al. (21) claimed that the extent of hypometabolism 
and peak Z-scores were influenced by the software calcula-
tion method rather than by different spatial normalization 
parameters. In the present comparative study, PEZ concordance 
was lower for 3D-SSP (25/35) than for SPM (29/35) in the entire 
cohort, but similar in the surgical patients (14/19 vs. 15/19). 
Excluding the 13 cases identified both by 3D-SSP and SPM, 
3D-SSP but not SPM was concordant with PEZ in surgical cases 
5 and 8, while SPM but not 3D-SSP was concordant with PEZ for 
surgical cases 12 and 13. Case 5 was HS/m_T sclerosis, and case 8 
was encephalitis, while cases 12 and 13 were both FCD. 3D-SSP 
was reported to be less affected by the presence of atrophy than 
SPM in patients with AD (30), which is in agreement with our 
results as cases 5 and 8 showed more severe atrophy than cases 
FigUre 5 | PeT imaging results of three cases with non-favorable outcome. In each panel, the upper part is the SPM-PET result (P < 0.001, voxel size 
200 corrected), and the lower part is the SD-SSP-PET result with Z-score. (a) Case 8 was diagnosed with encephalitis by postoperative pathological diagnosis. 
He received right posterior temporal lobe lesion resection with a very poor outcome (Engel IV). Both the SPM-PET and the 3D-SSP-PET result maps reveal a 
hypometabolic region in right temporal lobe. SPM-PET also shows another hypometabolic area in the right Sylvian fissure extending from the insula. However, the 
3D-SSP-PET result map shows a diffuse hypometabolic distribution in the right parietal lobe and frontal lobe. (B) Case 12 underwent right insular lesion resection 
according to PEZ with a postoperative outcome of Engel III. The SPM-PET result map shows another epileptic locus in the right posterior central gyrus. In addition 
to a hypometabolic region in the right Sylvian fissure extending from the insula, the posterior central gyrus region shows a high Z-score in the 3D-SSP result. 
(c) Case 17 underwent left anterior temporal lobectomy with a non-favorable outcome (Engel III). SPM-PET and 3D-SSP-PET result maps show ideal consistency 
in the localization of a hypometabolic region in the left temporal lobe. Failure of seizure control may have resulted from removal of a region smaller than the real 
epileptic zone to avoid functional loss.
FigUre 4 | Diagnostic accuracy of each imaging modality among the 19 surgical patients. The columns represent the number of modalities consistent with 
PEZ for each case.
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12 and 13. This indicates that the sensitivity of 3D-SSP depends 
on the histopathological type of epileptic foci. In some relatively 
deep medial cortical or subcortical regions, such as the medial 
supplementary motor area (SMA) and insula, 3D-SSP concord-
ance with PEZ was substantially lower than SPM. Nonetheless, 
3D-SSP was superior to visual analysis (71 vs. 40%) and MRI (71 
vs. 26%). Further, SPM appeared to better localize multiple foci, 
while 3D-SSP yielded only a diffuse hypometabolic region. In 
the present study, 16 patients who received VNS or antiepileptic 
drugs are often with complex lesions, such as bilateral epileptic 
foci, multi-lobe sites, or some lesions related to brain functional 
areas. SPM localized the PEZ-defined lesions in 15 of 16 cases, 
compared to 10 of 16 cases by the 3D-SSP, and showed a higher 
consistency rate (94 vs. 67%, P =  0.125, k = −0.12). What’s 
more, most reported voxel-based 18F-FDG-PET epileptic focus 
studies adopted the SPM methods in the current paper and the 
published literatures we can retrieve, the 3D-SSP application in 
this field can overcome the selection bias.
The SPM-PET analytical method has been used for the presur-
gical localization of epileptic foci for over 15 years (31, 32), and 
its clinical utility has been confirmed in both adult and pediatric 
epilepsy patients (9). Like the general significance test model, its 
FigUre 6 | PeT imaging results of three cases with favorable outcome but were discordant between sPM and 3D-ssP. In each panel, the upper part is 
the SPM-PET result (P < 0.001, voxel size 50 corrected), and the lower part is the SD-SSP-PET result with Z-score. (a) Case 5, the PEZ was localized at the right 
temporal lobe and underwent right anterior temporal lobe lesion resection. 3D-SSP showed a CS result with the PEZ of the right temporal lobe hypometabolism; 
however, SPM results were focused on the right occipital lobe hypometabolism. Considering the postsurgical pathology, the SPM result seemed untrustworthy. 
(B) Case 13, the right temporal and frontal lobes were considered to be PEZ. Overlapping hypometabolism regions were detected by SPM. In contrast, 3D-SSP 
only detected the epileptic focus in the right temporal lobe. Even though a very small metabolism was also found in the right frontal lobe by 3D-SSP, it is too small to 
account it as an epileptic focus, given the similar metabolism in the same position of the contralateral hemisphere. (c) Case 7, the PEZ was situated at the left 
temporal lobe and was confirmed by the postsurgical pathology. However, both 3D-SSP and SPM detected the hypometabolism of the left prefrontal lobe, not the 
temporal lobe.
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accuracy for epileptic foci localization depends on the statistical 
threshold and the voxel size, but the optimal tradeoff between 
these two parameters is still undefined. The SPM software default 
statistical threshold is P < 0.001, but there is no recommended 
cluster extent threshold. To date, most researchers have adopted 
thresholds of P = 0.01, 0.001, or 0.0001, false discovery rate (FDR) 
corrected P = 0.05, or family-wise (FWE) corrected P = 0.01, and 
most studies have set the voxel size to >50, 100, or 200 (9, 33, 
34). Although some researchers have found that all parameters 
perform similarly well for the detection of epileptic foci (9), our 
experience is that the size of the lesion correlates with the extent 
of resection and functional loss. Here, we introduce a process 
to optimize SPM analysis. The most important factor is the 
statistical threshold of P. In our routine work, we use a threshold 
gradient of P = 0.001, 0.01, and 0.05. Second, an ascending voxel 
size gradient (50, 100, and 200) is recommended. The optimal 
result is chosen based on maintaining an unchanging central 
hypometabolic region among at least two voxel sizes under one 
or two conditions of P values simultaneously. With this method, 
we can detect hypometabolic brain regions that would be missed 
if we selected an inappropriate control group, thereby increasing 
the detection rate of negative SPM results. Here, we attach little 
importance to the statistical threshold correction by FDR or FWE 
for EZ localization in individual patients, and agree with Kumar 
et al. who found that uncorrected statistical thresholds performed 
well in obtaining clinically useful results for lobar localization. 
Alternatively, the stricter corrected threshold, though highly 
specific, yielded unacceptably low sensitivity.
Following this method, SPM-PET analysis presented the high-
est concordant rate with the PEZ and detected single epileptic 
foci missed by 3D-SSP, visual-PET, and MRI, and even multiple 
epileptic foci not detected by video-EEG and other clinical data. 
Thus, SPM-PET evaluation can define the optimum minimum 
epileptic focus for “subtotal” resection. In contrast, 3D-SSP 
defined a more diffuse EZ within a relatively larger brain volume. 
Seizures arising from medial (parasagittal) cortical foci are often 
challenging to identify for surgical resection. Thus, we confirm 
the findings of Kumar et al. that SPM appears to be a particularly 
useful approach for detecting medially located seizure foci.
Despite the lower concordance with PEZ compared to SPM, 
3D-SPP was still much more accurate than visual-PET and MRI. 
Moreover, the 3D-SPP analytic procedure employs a more user-
friendly graphical interface than that used for SPM, and the pro-
gram produces color scaled Z-score maps from which the number 
of SDs from the mean of normal subjects is easily read, especially 
for the novice, allowing them to achieve the same detection accu-
racy as expert brain FDG-PET readers. In addition, the 3D-SPP 
program has built-in age-matched and normal databases that may 
obviate the need for a normal control group. However, although a 
Z-score of 1.5 or greater is regarded as indicative of pathology in 
AD diagnosis, the best threshold Z-score for epilepsy has not been 
established. The 3D-SSP shows results relative to four specific 
regions (GLB-global brain, thalamus, cerebellum, and pons), and 
these four comparators may reduce errors arising from a single 
comparator. In addition, 3D-SSP has greater software efficiency 
and operability, requires no previous programing experience, 
which was indispensable for learning SPM, and according to our 
experience, beginners can master 3D-SSP within a day, whereas 
2  weeks or more time would be needed for learning SPM. 
Furthermore, length of time per patient with each analysis was 
shorter for 3D-SSP than for SPM, with about 2 min for 3D-SSP 
and 10 min or much longer for the latter. We strongly recommend 
3D-SSP for routine epileptic localization due to the fast analysis 
procedure and relatively high accuracy.
Accurate localization of epileptic foci is critical for prognosis 
and to weighing surgical risks against postoperative benefits 
(4,  35). While both 3D-SSP- and SPM-PET analyses are more 
concordant with PEZ, MRI reveals the distinct anatomical 
9Wang et al. Kailiang Wang et al. 3D-SSP
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 164
structure around the focus that is essential for resection surgery, 
and EEG is still the gold standard for diagnosis of epilepsy. Thus, 
integration of multimodal neuroimaging, electrophysiology, and 
semiology provides the most reliable presurgical evaluation.
This study has several limitations. First, our patient selection 
criteria may have led to an underestimation of MRI sensitivity, 
as cases requiring only MRI or with obvious MRI deformation 
were excluded. Since more concerned with PET results, here, 
we introduced only MRI visual analysis results, and quantitative 
analysis of structural MRI was not used. Therefore, it is expected 
decreased MRI accuracy. Second, the standard for EZ localization 
(PEZ) was defined by video-EEG, clinical evaluation, and neu-
ropsychological data. Therefore, PEZ is not absolutely definitive, 
and in some cases, PEZ and EZ did not match, especially in the 
VNS and AEDS groups in which the PEZ was not consistent with 
pathology findings. However, in the surgical subset (19/35), the 
PEZ-defined region was verified by histopathology. Third, the 
present PET studies were limited to FDG. Other PET tracers, such 
as tracers labeled with 11C (36), may show different concordance 
rates among PEZ, MRI, SPM, 3D-SSP, and visual-PET.
cOnclUsiOn
Three-dimensional stereotactic surface projection and SPM 
18F-FDG-PET assessment provided important complementary 
presurgical information that was concordant with PEZ in 32/35 of 
our samples. Computational PET analysis was particularly useful 
in those cases in which MRI and visual-PET did not identify an 
epileptogenic focus. SPM concordance was higher than 3D-SSP 
concordance. We believe that a correct interpretation of hypo-
metabolic epileptic foci should integrate both SPM and 3D-SSP 
18F-FDG-PET evaluation; 3D-SSP is recommended for primary 
evaluation due to software efficiency and operability, while SPM 
is recommended for deeper foci and more accurate localization. 
These techniques may extend the possibility of surgical treatment 
to patients previously considered inoperable.
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